EMA/390359/2014

European Medicines Agency decision

P/0196/2014

of 8 August 2014

on the acceptance of a modification of an agreed paediatric investigation plan for sildenafil (Revatio), (EMEA-000671-PIP01-09-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0196/2014

of 8 August 2014

on the acceptance of a modification of an agreed paediatric investigation plan for sildenafil (Revatio), (EMEA-000671-PIP01-09-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/33/2010 issued on 17 March 2010, the decision P/114/2011 issued on 6 May 2011, the decision P/0070/2012 issued on 4 April 2012, the decision P/0158/2012 issued on 25 July 2012, and the decision P/0165/2013 issued on 29 July 2013,

Having regard to the application submitted by Pfizer Limited on 21 March 2014 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 20 June 2014, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for sildenafil (Revatio), film-coated tablet, powder for oral suspension, solution for injection, oral use, intravenous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ – Sandwich, United Kingdom.

Done at London, 8 August 2014

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/207997/2014

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000671-PIP01-09-M05

Scope of the application

Active substance(s):

Sildenafil

Invented name:

Revatio

Condition(s):

Treatment of pulmonary arterial hypertension

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Powder for oral suspension

Solution for injection

Route(s) of administration:

Oral use

Intravenous use

Name/corporate name of the PIP applicant:

Pfizer Limited

Information about the authorised medicinal product:

See Annex II

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Pfizer Limited submitted to the European Medicines Agency on 21 March 2014 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/33/2010 issued on 17 March 2010, the decision P/114/2011 issued on 6 May 2011, the decision P/0070/2012 issued on 4 April 2012, the decision P/0158/2012 issued on 25 July 2012, and the decision P/0165/2013 issued on 29 July 2013.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 23 April 2014.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

London, 20 June 2014

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition: treatment of pulmonary arterial hypertension

2.1.1. Indication(s) targeted by the PIP

Treatment of Persistent Pulmonary Hypertension of the Newborn (PPHN)

Treatment of Pulmonary Arterial Hypertension (PAH)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

- From birth to less than 18 years;
- Birth to less than 1 month of age: PPHN;
- From 1 month to less than 18 years of age: PAH.

2.1.3. Pharmaceutical form(s)

- Film-coated tablet for oral use in children 6 years and older
- Powder for oral suspension for children less than 6 years of age
- Solution for injection 0.8 mg/mL in 20 mL and 50 mL vials

2.1.4. Studies

Area	Number of measures	Description
Quality-related studies	1	**Study 1** Powder for oral suspension for children less than 6 years of age.
Non-clinical studies	0	Not applicable.
Clinical studies	4	**Pulmonary Arterial Hypertension** **Study 2** A1481131: Randomized, double-blind, placebo-controlled, dose-ranging, parallel group study of oral sildenafil in the treatment of children with pulmonary arterial hypertension. **Study 3** A1481156: A multicentre long-term extension study to assess the safety of oral sildenafil in the treatment of subjects who have completed study A1481131.

		Persistent Pulmonary Hypertension of the Newborn. **Study 4** A1481157: 7-day open-label, multicentre pharmacokinetic study of sildenafil in newborns with persistent pulmonary hypertension. **Study 5** A1481316: Multicentre, randomized, blinded, controlled, 2-arm, parallel-group study to evaluate the efficacy and safety of the combination of IV sildenafil and iNO for the treatment of neonates with PPHN or hypoxic respiratory failure at risk for PPHN

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes.
Date of completion of the paediatric investigation plan:	By July 2015.
Deferral for some or all studies contained in the paediatric investigation plan:	Yes.

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of pulmonary arterial hypertension

Authorised indication(s):

- Treatment of patients with pulmonary arterial hypertension classified as WHO functional class II and III to improve exercise capacity.

Authorised pharmaceutical form(s):

Film-coated tablet, suspension for injection, powder for oral suspension

Authorised route(s) of administration:

Oral use, intravenous use